BPC-157

Classification

Synthetic gastric pentadecapeptide (research only)

Approval status

Research only · Not approved for human use

Research status

Investigational pentadecapeptide. Not an approved human therapeutic in Australia, the US or the EU.

Molecular formula

C62H98N16O22

Molecular weight

1419.5 g·mol⁻¹

Sequence

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (BPC-157 pentadecapeptide)

Primary biological target

Proposed: angiogenic and nitric-oxide related pathways; growth-factor signalling. Mechanism not yet fully established in humans.

Half-life

Insufficient reliable evidence identified for a validated human plasma half-life.

Routes investigated

Oral (preclinical and limited human reports), Intraperitoneal / subcutaneous (animal), Topical (preclinical)

Human evidence level

C — Limited or early human evidence

A laboratory peptide with extensive preclinical injury-model literature and very limited high-quality human trials. It is not an approved medicine. Longevity Protocol does not sell BPC-157.

Synthetic fragment derived from a gastric protein sequence studied mainly in animal models of injury.

Mechanism not yet fully established.

Proposed mechanism: BPC-157 has been reported in preclinical literature to influence angiogenesis, nitric oxide signalling and growth-factor related repair pathways. Binding to a single validated human drug receptor comparable to GLP-1 agonists has not been established. Mechanism not yet fully established. Observed animal-model findings should not be read as proven human tissue repair.

Unknown at pharmaceutical quality, dose and route in well-controlled human studies. Anecdotal internet use is not evidence.

• Soft-tissue injury models

  D · Primarily animal / preclinical evidence

  Preclinical studies suggest effects in rodent tendon, ligament and muscle-injury models. These are not demonstrated clinical indications.^[1]

• Gastrointestinal injury models

  D · Primarily animal / preclinical evidence

  Animal studies have examined experimental GI lesions. Early human research is sparse and not registrational.^[1]

Investigational findings are not proven clinical benefits unless an authority has labelled that indication.

Overall human evidence grade: C · Limited or early human evidence

Animal, cell and in-vitro findings are listed separately from human effects.

• Animal experimental: Rodent tendon and muscle injury

  Preclinical studies suggest improved healing metrics in some injury models. Species, injury method and dose are not interchangeable with human practice.

  Limitations: Do not convert mg/kg animal doses to human treatment schedules.

  ^[1]

This section does not provide personalised medical dosing. Values are those reported in papers or protocols. Animal mg/kg doses are not converted to human doses.

Doses reported in human studies

Insufficient reliable evidence identified.

Preclinical / animal study dosing

1. Representative rodent BPC-157 injury models (literature range)

   Dose: Typically microgram/kg intraperitoneal or oral ranges in cited reviews — verify each paper µg/kg (animal)

   Route: Intraperitoneal, oral or topical depending on experiment

   Frequency: Study-specific

   Duration: Study-specific

   Model: Rats / mice (varies by paper)

   Purpose: Experimental tissue-injury pharmacology

   ^[1]

Reliable human pharmacokinetic data were not identified. Do not infer human half-life from rodent papers.

A systematic human adverse-event profile comparable to labelled drugs was not identified.

Serious events. Unknowns include contamination, mislabelling and infection risk from unregulated injectables.

Long-term safety. Long-term human safety is unknown.

Unknowns. No evidence of harm in a given animal paper does not mean the compound is safe in people.

Contraindications. Not for human use. Not for compounding as a wellness injection. WADA prohibited as an unapproved substance in sport.

Australia — TGA

Not approved as a human therapeutic medicine for tissue repair. Research-chemical listings are not ARTG-registered medicines.

United States — FDA

Not approved. FDA has warned about unapproved peptide compounding including BPC-157 in compounding contexts.

European Union — EMA

Not authorised as a human peptide medicine for the grey-market indications advertised online.

1. [1] Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications

   Sikiric P et al. Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications Curr Neuropharmacol. 2016. PMID 27165480

   PMID 27165480

2. [2] FDA communications on unapproved peptide compounding (BPC-157 listed among peptides of concern in compounding policy discussions)

   U.S. Food and Drug Administration FDA communications on unapproved peptide compounding (BPC-157 listed among peptides of concern in compounding policy discussions) 2023

   Open source